Magnesium: Potential roles in neurovascular disease

Frontiers in Neurology

Volumn 5 APR, Issue , 2014, Pages

  Chang, Jason J ^a   Mack, William J ^b   Saver, Jeffrey L ^c   Sanossian, Nerses ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

All cerebrovascular disease stroke; Intracerebral hemorrhage; Magnesium; Neuroprotection; Subarachnoid hemorrhage

Indexed keywords

MAGNESIUM; MAGNESIUM SULFATE; PLACEBO;

BRAIN HEMORRHAGE; BRAIN HYPOXIA; BRAIN INFARCTION; BRAIN ISCHEMIA; CAROTID ENDARTERECTOMY; CEREBROVASCULAR DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EXTRACORPOREAL CIRCULATION; HEART ARREST; HUMAN; INFANT DISEASE; MAGNESIUM BLOOD LEVEL; META ANALYSIS (TOPIC); MOTOR DYSFUNCTION; NEUROPROTECTION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUBARACHNOID HEMORRHAGE; TREATMENT OUTCOME;

EID: 84901014858     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2014.00052     Document Type: Review

References (61)

1. World Stroke Campaign: Facts and Figures [Internet] (2014). [cited 2014 Apr 3]. Availbale from: http://www.worldstrokecampaign.org/Facts/Pages/StrokeFacts.aspx.
2. Stroke Facts: Stroke in the United States [Internet] (2009). [cited 2014 Apr 3]. Available from: http://www.cdc.gov/stroke/facts.htm.
3. Smith DA, Connick JH, Stone TW. Effect of changing extracellular levels of magnesium on spontaneous activity and glutamate release in the mouse neocortical slice. Br J Pharmacol (1989) 97:475-82. doi:10.1111/j.1476-5381.1989.tb11975.x.
4. Bartrup JT, Stone TW. Presynaptic actions of adenosine are magnesium-dependent. Neuropharmacology (1988) 27:761-3. doi:10.1016/0028-3908(88)90087-1.
5. Imer M, Omay B, Uzunkol A, Erdem T, Sabanci PA, Karasu A, et al. Effect of magnesium, MK-801 and combination of magnesium and MK-801 on blood-brain barrier permeability and brain edema after experimental traumatic diffuse brain injury. Neurol Res (2009) 31:977-81. doi:10.1179/174313209X385617.
6. Nowak L, Bregestovski P, Ascher P, Herbet A, Prochiantz A. Magnesium gates glutamate-activated channels in mouse central neurones. Nature (1984) 307:462-5. doi:10.1038/307462a0.
7. Vink R, McIntosh TK, Demediuk P, Weiner MW, Faden AI. Decline in intracellular free Mg2+ is associated with irreversible tissue injury after brain trauma. J Biol Chem (1988) 263:757-61.
8. Iseri LT, French JH. Magnesium: nature's physiologic calcium blocker. Am Heart J (1984) 108:188-93. doi:10.1016/0002-8703(84)90572-6.
9. Kemp PA, Gardiner SM, Bennett T, Rubin PC. Magnesium sulphate reverses the carotid vasoconstriction caused by endothelin-I, angiotensin II and neuropeptide-Y, but not that caused by NG-nitro-L-arginine methyl ester, in conscious rats. Clin Sci (1993) 85:175-81.
10. Kemp PA, Gardiner SM, March JE, Rubin PC, Bennett T. Assessment of the effects of endothelin-1 and magnesium sulphate on regional blood flows in conscious rats, by the coloured microsphere reference technique. Br J Pharmacol (1999) 126:621-6.
11. Sharma N, Cho DH, Kim SY, Bhattarai JP, Hwang PH, Han SK. Magnesium sulfate suppresses L-type calcium currents on the basilar artery smooth muscle cells in rabbits. Neurol Res (2012) 34:291-6. doi:10.1179/1743132812Y.0000000016.
12. Izumi Y, Roussel S, Pinard E, Seylaz J. Reduction of infarct volume by magnesium after middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab (1991) 11:1025-30. doi:10.1038/jcbfm.1991.170.
13. Chakraborti S, Chakraborti T, Mandal M, Mandal A, Das S, Ghosh S. Protective role of magnesium in cardiovascular diseases: a review. Mol Cell Biochem (2002) 238:163-79. doi:10.1023/A:1019998702946.
14. Reinhart RA. Clinical correlates of the molecular and cellular actions of magnesium on the cardiovascular system. Am Heart J (1991) 121:1513-21. doi:10.1016/0002-8703(91)90160-J.
15. Amighi J, Sabeti S, Schlager O, Mlekusch W, Exner M, Lalouschek W, et al. Low serum magnesium predicts neurological events in patients with advanced atherosclerosis. Stroke (2004) 35:22-7. doi:10.1161/01.STR.0000105928.95124.1F.
16. Liao F, Folsom AR, Brancati FL. Is low magnesium concentration a risk factor for coronary heart disease? The atherosclerosis risk in communities (ARIC) study. Am Heart J (1998) 136:480-90. doi:10.1016/S0002-8703(98)70224-8.
17. Bayir A, Ak A, Kara H, Sahin TK. Serum and cerebrospinal fluid magnesium levels, Glasgow coma scores, and in-hospital mortality in patients with acute stroke. Biol Trace Elem Res (2009) 130:7-12. doi:10.1007/s12011-009-8318-9.
18. Pasternak K, Wronska J, Dabrowski W, Sztanke M. Blood magnesium concentration and dopamine or dobutamine infusion demand in patients during CABG (coronary artery bypass grafting) with normovolemic haemodilution. Magnes Res (2006) 19:261-7. doi:10.1684/mrh.2006.0070.
19. Thurnau GR, Kemp DB, Jarvis A. Cerebrospinal fluid levels of magnesium in patients with preeclampsia after treatment with intravenous magnesium sulfate: a preliminary report. Am J Obstet Gynecol (1987) 157:1435-8. doi:10.1016/S0002-9378(87)80239-9.
20. Sjostrom I, Wester P. Systematically induced hypermagnesemia increases the bioavailability of magnesium in rat brain. Soc Neurosci Abstr (1994) 20:181.
21. Kapaki E, Segditsa J, Papageorgiou C. Zinc, copper and magnesium concentration in serum and CSF of patients with neurological disorders. Acta Neurol Scand (1989) 79:373-8. doi:10.1111/j.1600-0404.1989.tb03803.x.
22. McKee JA, Brewer RP, Macy GE, Phillips-Bute B, Campbell KA, Borel CO, et al. Analysis of the brain bioavailability of peripherally administered magnesium sulfate: a study in humans with acute brain injury undergoing prolonged induced hypermagnesemia. Crit Care Med (2005) 33:661-6. doi:10.1097/01.CCM.0000156293.35868.B2.
23. Muir KW, Lees KR. A randomized, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. Stroke (1995) 26:1183-8.
24. Muir KW, Lees KR. Dose optimization of intravenous magnesium sulfate after acute stroke. Stroke (1998) 29:918-23.
25. Bradford APJ, Muir KW, Lees KR, Group IS. Images pilot study of intravenous magnesium in acute stroke. Cerebrovasc Dis (1998) 8:86A.
26. Lampl Y, Gilad R, Geva D, Eshel Y, Sadeh M. Intravenous administration of magnesium sulfate in acute stroke: a randomized double-blind study. Clin Neuropharmacol (2001) 24:11-5. doi:10.1097/00002826-200101000-00003.
27. Saver JL, Kidwell C, Eckstein M, Starkman S; FAST-MAG Pilot Trial Investigators. Prehospital neuroprotective therapy for acute stroke: results of the field administration of stroke therapy-magnesium (FAST-MAG) pilot trial. Stroke (2004) 35:e106-8. doi:10.1161/01.STR.0000124458.98123.52.
28. Muir KW, Lees KR, Ford I, Davis S; Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators. Magnesium efficacy in stroke study, magnesium for acute stroke (intravenous magnesium efficacy in stroke trial): randomised controlled trial. Lancet (2004) 363:439-45. doi:10.1016/S0140-6736(04)15490-1.
29. Muir KW. Systematic review of clinical trials of magnesium for acute stroke. Stroke (2001) 31:379A.
30. Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med (2013) 368:2355-65. doi:10.1056/NEJMoa1214609.
31. Veyna RS, Seyfried D, Burke DG, Zimmerman C, Mlynarek M, Nichols V, et al. Magnesium sulfate therapy after aneurysmal subarachnoid hemorrhage. J Neurosurg (2002) 96:510-4. doi:10.3171/jns.2002.96.3.0510.
32. Wong GK, Chan MT, Boet R, Poon WS, Gin T. Intravenous magnesium sulfate after aneurysmal subarachnoid hemorrhage: a prospective randomized pilot study. J Neurosurg Anesthesiol (2006) 18:142-8. doi:10.1097/00008506-200604000-00009.
33. van den Bergh WM, Algra A, van Kooten F, Dirven CM, van Gijn J, Vermeulen M, et al. Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial. Stroke (2005) 36:1011-5. doi:10.1161/01.STR.0000160801.96998.57.
34. Wong GK, Poon WS, Chan MT, Boet R, Gin T, Ng SC, et al. Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage (IMASH): a randomized, double-blinded, placebo-controlled, multicenter phase III trial. Stroke (2010) 41:921-6. doi:10.1161/STROKEAHA.109.571125.
35. Dorhout Mees SM, Algra A, Vandertop WP, van Kooten F, Kuijsten HA, Boiten J, et al. Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial. Lancet (2012) 380:44-9. doi:10.1016/S0140-6736(12)60724-7.
36. Longstreth WT Jr, Fahrenbruch CE, Olsufka M, Walsh TR, Copass MK, Cobb LA. Randomized clinical trial of magnesium, diazepam, or both after out-of-hospital cardiac arrest. Neurology (2002) 59:506-14. doi:10.1212/WNL.59.4.506.
37. Mittendorf R, Covert R, Boman J, Khoshnood B, Lee KS, Siegler M. Is tocolytic magnesium sulphate associated with increased total paediatric mortality? Lancet (1997) 350:1517-8. doi:10.1016/S0140-6736(97)24047-X.
38. Basu SK, Chickajajur V, Lopez V, Bhutada A, Pagala M, Rastogi S. Immediate clinical outcomes in preterm neonates receiving antenatal magnesium for neuroprotection. J Perinat Med (2012) 40:185-9. doi:10.1515/JPM.2011.094.
39. Wolf HT, Hegaard HK, Greisen G, Huusom L, Hedegaard M. Treatment with magnesium sulphate in pre-term birth: a systematic review and meta-analysis of observational studies. J Obstet Gynaecol (2012) 32:135-40. doi:10.3109/01443615.2011.638999.
40. Doyle LW, Crowther CA, Middleton P, Marret S. Antenatal magnesium sulfate and neurologic outcome in preterm infants: a systematic review. Obstet Gynecol (2009) 113:1327-33. doi:10.1097/AOG.0b013e3181a60495.
41. Crowther CA, Hiller JE, Doyle LW, Haslam RR; Australasian Collaborative Trial of Magnesium Sulphate Collaborative. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA (2003) 290:2669-76. doi:10.1001/jama.290.20.2669.
42. Marret S, Marpeau L, Zupan-Simunek V, Eurin D, Leveque C, Hellot MF, et al. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial*. BJOG (2007) 114:310-8. doi:10.1111/j.1471-0528.2006.01162.x.
43. Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer BM, et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med (2008) 359:895-905. doi:10.1056/NEJMoa0801187.
44. Di Renzo GC, Mignosa M, Gerli S, Burnelli L, Luzi G, Clerici G, et al. The combined maternal administration of magnesium sulfate and aminophylline reduces intraventricular hemorrhage in very preterm neonates. Am J Obstet Gynecol (2005) 192:433-8. doi:10.1016/j.ajog.2004.07.078.
45. Bhudia SK, Cosgrove DM, Naugle RI, Rajeswaran J, Lam BK, Walton E, et al. Magnesium as a neuroprotectant in cardiac surgery: a randomized clinical trial. J Thorac Cardiovasc Surg (2006) 131:853-61. doi:10.1016/j.jtcvs.2005.11.018.
46. Chiu C, Heyer EJ, Rampersad AD, Zurica J, Ornstein E, Sahlein DH, et al. High dose magnesium infusions are not associated with increased pressor requirements after carotid endarterectomy. Neurosurgery (2006) 58:71-7. doi:10.1227/01.NEU.0000190662.71046.66.
47. Mack WJ, Kellner CP, Sahlein DH, Ducruet AF, Kim GH, Mocco J, et al. Intraoperative magnesium infusion during carotid endarterectomy: a double-blind placebo-controlled trial. J Neurosurg (2009) 110:961-7. doi:10.3171/2008.9.17671.
48. Kidwell CS, Liebeskind DS, Starkman S, Saver JL. Trends in acute ischemic stroke trials through the 20th century. Stroke (2001) 32:1349-59. doi:10.1161/01.STR.32.6.1349.
49. DeGraba TJ, Pettigrew LC. Why do neuroprotective drugs work in animals but not humans? Neurol Clin (2000) 18:475-93. doi:10.1016/S0733-8619(05)70203-6.
50. Stroke Therapy Academic Industry Roundtable II (STAIR-II). Recommendations for clinical trial evaluation of acute stroke therapies. Stroke (2001) 32:1598-606. doi:10.1161/01.STR.32.7.1598.
51. Gorelick PB. Neuroprotection in acute ischaemic stroke: a tale of for whom the bell tolls? Lancet (2000) 355:1925-6. doi:10.1016/S0140-6736(00)02318-7.
52. De Keyser J, Sulter G, Luiten PG. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? Trends Neurosci (1999) 22:535-40. doi:10.1016/S0166-2236(99)01463-0.
53. Fisher M, New RR. New perspectives on developing acute stroke therapy. Ann Neurol (2003) 53:10-20. doi:10.1002/ana.10407.
54. Ovbiagele B, Kidwell CS, Starkman S, Saver JL. Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep (2003) 3:9-20. doi:10.1007/s11910-003-0031-z.
55. Wahlgren N, Ahmed N. Neuroprotection in cerebral ischaemia: facts and fancies-the need for new approaches. Cerebrovasc Dis (2004) 17(Suppl 1):153-66. doi:10.1159/000074808.
56. Muir KW, Teal PA. Why have neuro-protectants failed?: lessons learned from stroke trials. J Neurol (2005) 252:1011-20. doi:10.1007/s00415-005-0933-6.
57. Ferguson KN, Kidwell CS, Starkman S, Saver JL. Hyperacute treatment initiation in neuroprotective agent stroke trials. J Stroke Cerebrovasc Dis (2004) 13:109-12. doi:10.1016/j.jstrokecerebrovasdis.2004.04.001.
58. Sanossian N, Kim-Tenser M. Field neuroprotective therapy followed by intravenous thrombolysis in a phase 3 clinical trial. Stroke (2012) 43:A65.
59. Campbell K, Meloni BP, Zhu H, Knuckey NW. Magnesium treatment and spontaneous mild hypothermia after transient focal cerebral ischemia in the rat. Brain Res Bull (2008) 77:320-2. doi:10.1016/j.brainresbull.2008.08.017.
60. Zhu H, Meloni BP, Moore SR, Majda BT, Knuckey NW. Intravenous administration of magnesium is only neuroprotective following transient global ischemia when present with post-ischemic mild hypothermia. Brain Res (2004) 1014:53-60. doi:10.1016/j.brainres.2004.03.073.
61. Song W, Wu YM, Ji Z, Ji YB, Wang SN, Pan SY. Intra-carotid cold magnesium sulfate infusion induces selective cerebral hypothermia and neuroprotection in rats with transient middle cerebral artery occlusion. Neurol Sci (2012) 34(4):479-86. doi:10.1007/s10072-012-1064-3.